Article

NovaBay unveils new lid, lash cleanser

NovaBay Pharmaceuticals has unveiled a new eye-care product, the i-Lid Cleanser.

 

Emeryville, CA-NovaBay Pharmaceuticals has unveiled a new eye-care product, the i-Lid Cleanser.

The product, which was introduced at last week’s American Society of Cataract/Refractive Surgery annual symposium and congress in Boston, aims to help patients with irritation of their eyelids by cleaning the lids and lashes, removing debris and microorganisms that lead to vision problems.

The cleanser has already been cleared by the FDA through its 510(k) process.

“I believe ophthalmologists and optometrists will find that NovaBay’s innovative (cleanser) offers significant advantages over currently marketed products which are merely ‘detergent based’ lid and lash cleansers, which offer little to no benefit,” said Ron Najafi, PhD, chief executive officer and chairman of NovaBay Pharmaceuticals.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.